Crossmark

Timing of hemoadsorption in sepsis: redefining early through mediator-guided therapy

Published Online: 2026-08-25

Authors

Kusirisin, Prit

Kellum, John A.

Srisawat, Nattachai https://orcid.org/0000-0002-8544-8132
License Information

Text and Data Mining valid from 2026-08-25

Version of Record valid from 2026-08-25
More Information

Article History

Received: 17 July 2026

Accepted: 19 August 2026

First Online: 25 August 2026

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Competing interests: JAK discloses the following: Employment/stock: Spectral Medical; Consultancy: AstraZeneca, Baxter, Bayer, BioPorto, Chugai Pharma, Mitsubishi Tanabe; Licensed patents held by the University of Pittsburgh: Cytosorbents, J3RM. NS has received research funding from the US National Institutes of Health (P01AI168148 and R01AI183353 for leptospirosis research) and Jafron (DPMAS project). The remaining authors declare that they have no competing interests.

Document is current